Tamara T Monesmith from Methuen, MA, age 53

Resumes

Vice President, Process And Analytical Development

view source

Location:

7 Sequoia Dr, Methuen, MA

Industry:

Biotechnology

Work:

Argos Therapeutics since Jan 2008
Director, Manufacturing & Process Development
Argos Therapeutics Apr 2007 - Jan 2008
Director, Process Development and Project Management, Oncology
Argos Therapeutics Aug 2002 - Apr 2007
Process Development (Director, Sr. Manager, Manager, Supervisor, Sr. Engineer)
Argos Therapeutics Feb 2002 - Jul 2002
Production Engineer
Biolex Jan 1999 - Feb 2002
Sr. Process Design Engineer / Process Design Engineer

Education:

North Carolina State University 1996 - 1999
MS, Biological Engineering University of Arizona 1989 - 1994
BS, Chemical Engineering

Skills:

Biotechnology
Biopharmaceuticals
Gmp
Technology Transfer
U.s. Food and Drug Administration
Process Simulation
Standard Operating Procedure
Validation

Us Patents

Dendritic Cell Compositions And Methods
view source
US Patent:

8501470, Aug 6, 2013
Filed:

Jan 17, 2012
Appl. No.:

13/351510
Inventors:

Tamara Monesmith - Durham NC, US
Irina Tcherepanova - Rougemont NC, US
Lois Dinterman - Kearneysville WV, US
Assignee:

Argos Therapeutics, Inc. - Durham NC
International Classification:

C12N 5/07
US Classification:

435325
Abstract:

Methods are provided for the production of dendritic cells from monocytes that have been incubated at a temperature of 1 C. -34 C. for a period of approximately 6 to 96 hours from the time they are isolated from a subject. After the incubation period, the monocytes can then be induced to differentiate into dendritic cells. Mature dendritic cells made by the methods of the invention have increased levels of one or more of CD80, CD83, CD86, MHC class I molecules, or MHC class II molecules as compared to mature dendritic cells prepared from monocytes that have not been held at 1 C. -34 C. for at least 6 hours from the time they were isolated from a subject. Dendritic cells made by the methods of the invention are useful for the preparation of vaccines and for the stimulation of T cells.

Dendritic Cell Compositions And Methods
view source
US Patent:

20090053251, Feb 26, 2009
Filed:

Apr 7, 2006
Appl. No.:

11/918076
Inventors:

Tamara Monesmith - Durham NC, US
Irina Tcherepanova - Rougemont NC, US
Lois Dinterman - Kearneysville WV, US
International Classification:

A61K 39/00
C12N 5/08
A61P 31/00
US Classification:

4241841, 435372
Abstract:

Methods are provided for the production of dendritic cells from monocytes that have been incubated at a temperature of 1 C.-34 C. for a period of approximately 6 to 96 hours from the time they are isolated from a subject. After the incubation period, the monocytes can then be induced to differentiate into dendritic cells. Mature dendritic cells made by the methods of the invention have increased levels of one or more of CD80, CD83, CD86, MHC class I molecules, or MHC class II molecules as compared to mature dendritic cells prepared from monocytes that have not been held at 1 C.-34 C. for at least 6 hours from the time they were isolated from a subject. Dendritic cells made by the methods of the invention are useful for the preparation of vaccines and for the stimulation of T cells.

Dendritic Cell Compositions And Methods
view source
US Patent:

20130280805, Oct 24, 2013
Filed:

Jun 28, 2013
Appl. No.:

13/929889
Inventors:

Tamara Monesmith - Durham NC, US
Irina Tcherepanova - Rougemont NC, US
Lois Dinterman - Kearneysville WV, US
International Classification:

C12N 5/0784
US Classification:

435372, 435377
Abstract:

Methods are provided for the production of dendritic cells from monocytes that have been incubated at a temperature of 1 C.-34 C. for a period of approximately 6 to 96 hours from the time they are isolated from a subject. After the incubation period, the monocytes can then be induced to differentiate into dendritic cells. Mature dendritic cells made by the methods of the invention have increased levels of one or more of CD80, CD83, CD86, MHC class I molecules, or MHC class II molecules as compared to mature dendritic cells prepared from monocytes that have not been held at 1 C.-34 C. for at least 6 hours from the time they were isolated from a subject. Dendritic cells made by the methods of the invention are useful for the preparation of vaccines and for the stimulation of T cells.

Methods And Uses For Dendritic Cell Therapy
view source
US Patent:

20210030791, Feb 4, 2021
Filed:

Nov 7, 2018
Appl. No.:

16/762314
Inventors:

- Durham NC, US
Mark DEBENEDETTE - Durham NC, US
Joseph HORVATINOVICH - Raleigh NC, US
Alex DUSEK - Chapel Hill NC, US
Tamara MONESMITH - Cambridge MA, US
International Classification:

A61K 35/15
A61K 39/00
G01N 33/50
Abstract:

This invention provides methods of evaluating immune system parameters to identify and treat patients who are likely to experience more favorable treatment outcomes. This invention also provides methods for treating a human patient with a dendritic cell therapy by obtaining at least one value or measurement of the level and/or amount of a particular type of treatment indicator in the patient, confirming that said value or measurement exceeds or is less than the treatment threshold value for that value or measurement, and administering said dendritic cell therapy to the patient.

Dendritic Cell Compositions And Methods
view source
US Patent:

20160102291, Apr 14, 2016
Filed:

Oct 9, 2015
Appl. No.:

14/879336
Inventors:

- Durham NC, US
Tamara Monesmith - Durham NC, US
Irina Tcherepanova - Rougemont NC, US
Lois Dinterman - Oxford NC, US
International Classification:

C12N 5/0784
Abstract:

Methods are provided for the production of dendritic cells from monocytes that have been incubated at a temperature of 1 C.-34 C. for a period of approximately 6 to 96 hours from the time they are isolated from a subject. After the incubation period, the monocytes can then be induced to differentiate into dendritic cells. Mature dendritic cells made by the methods of the invention have increased levels of one or more of CD80, CD83, CD86, MHC class I molecules, or MHC class II molecules as compared to mature dendritic cells prepared from monocytes that have not been held at 1 C.-34 C. for at least 6 hours from the time they were isolated from a subject. Dendritic cells made by the methods of the invention are useful for the preparation of vaccines and for the stimulation of T cells.

Dendritic Cell Compositions And Methods
view source
US Patent:

20150132844, May 14, 2015
Filed:

Jun 18, 2014
Appl. No.:

14/307991
Inventors:

- Durham NC, US
Tamara Monesmith - Durham NC, US
Irina Tcherepanova - Rougemont NC, US
Lois Dinterman - Oxford NC, US
International Classification:

C12N 5/0784
US Classification:

435347, 435377, 435372
Abstract:

Methods are provided for the production of dendritic cells from monocytes that have been incubated at a temperature of 1 C.-34 C. for a period of approximately 6 to 96 hours from the time they are isolated from a subject. After the incubation period, the monocytes can then be induced to differentiate into dendritic cells. Mature dendritic cells made by the methods of the invention have increased levels of one or more of CD80, CD83, CD86, MHC class I molecules, or MHC class II molecules as compared to mature dendritic cells prepared from monocytes that have not been held at 1 C.-34 C. for at least 6 hours from the time they were isolated from a subject. Dendritic cells made by the methods of the invention are useful for the preparation of vaccines and for the stimulation of T cells.